Harrow Posts Record Revenue but Faces Persistent Leverage and Regulatory Risks

What happened

Harrow announced record Q4 2025 revenue of $89.1 million, a 33% year-over-year increase, with full-year revenue reaching $272.3 million, up 36% from 2024, driven by strong performance in flagship brands like IHEEZO and VEVYE. Despite this top-line growth, the company reported a net loss of $5.1 million for 2025, highlighting ongoing profitability challenges that align with the DeepValue report's concerns about volatile earnings and high interest costs. Guidance for 2026 projects revenue of $350-$365 million and Adjusted EBITDA of $80-$100 million, suggesting management's confidence in continued expansion, but the report cautions that such projections are optimistic given historical net losses and execution risks. The master report emphasizes elevated leverage, with net debt/EBITDA at 8.21x and interest coverage of 0.58x, which could strain cash flow despite improved operating cash flow of $43.9 million in 2025. Regulatory scrutiny over the New Jersey outsourcing facility and competitive pressures in ophthalmology, as noted in the report, remain significant headwinds that temper the positive revenue narrative.

Implication

The improved revenue and operating cash flow in 2025 provide a glimmer of operational progress, but the persistent net loss and substantial debt burden limit financial flexibility and increase vulnerability to earnings shortfalls. Guidance for 2026, if achieved, could support deleveraging efforts, but execution risks in a crowded ophthalmic market and dependence on key products like VEVYE make this uncertain. Regulatory overhangs, such as FDA scrutiny of manufacturing facilities, pose ongoing threats to cash generation and could lead to operational disruptions, as highlighted in the DeepValue report. The stock's rich valuation, with negative earnings and high price-to-book ratios, may not fully reflect these downside risks, suggesting limited margin of safety for new investors. Existing shareholders should monitor debt metrics, cash flow trends, and regulatory developments closely, as sustained positive free cash flow and deleveraging are necessary to shift the risk-reward profile from potential sell to a more constructive view.

Thesis delta

The news of record revenue and positive operating cash flow in 2025 offers incremental support for Harrow's growth narrative, potentially easing near-term liquidity concerns highlighted in the DeepValue report. However, the persistent net loss, unchanged high leverage metrics, and ongoing regulatory risks do not fundamentally alter the 'POTENTIAL SELL' thesis, which remains based on valuation and balance-sheet fragility. Investors should see this update as modest progress rather than a transformative shift, maintaining a cautious stance until clearer evidence of sustained profitability and deleveraging emerges.